AstraZeneca Results Presentation Deck
BioPharmaceuticals: new launch medicines
Portfolio of new medicines across uses and markets
Europe $203m (+70%);
Japan $100m (+14%)
Leading biologic medicine
in many markets¹
US, total patient share
US $603m (+25%)
Leading novel biologic¹
100%
80%
60%
40%
20%
Fasenra
Severe asthma
0%
Q2 2017
Q4 2017
Q2 20
Cut Q4 2018
4 Q2 2019
Q4 2019
50.4%
49.6%
pQ2 2020
oQ4 2020
Total revenue at actual exchange rates. 1. Market shares are
total patient share in severe, uncontrolled asthma; specialty
pharmacies and 'buy and bill' market, IQVIA market research.
17
Breztri
COPD
EMs $14m
Ongoing launch in China;
Q4 impact by NRDL accrual
Japan $9m
~1/4 of new patients²;
year-end Ryotanki³ lift
US $5m
Early launch;
efficacy reso-
nates with
prescribers
ストリエアロスフィア
ピレーズトリ
エアロスフィア
56双入
初推式路社
GHASKA
2. IQVIA market research.
3. Ryotanki: regulation in Japan that restricts prescriptions for
medicines in their first year on the market to just two weeks.
TS
$m
30
20
10
0
Lokelma
Hyperkalaemia
Global $76m; US $57m
US market leadership4;
COVID-19 market impact
Japan accelerated; early
sales in China and Europe
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
T['s
US Europe
EROW
EMS
Total revenue at actual exchange rates. 4. Market leadership in
new-to-medicine patients, IQVIA market research.
$m
20
10
EMS
roxadustat
Anaemia in CKD
EMs $30m
China launch progressed;
$73m in-market sales; tens
of '000s of patients treated
US
Regulatory decision Q1 '21
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Collaboration revenue at actual exchange rates.
4View entire presentation